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Colorectal cancer has an annual incidence of 53 cases per 100 000
in the USA and Europe, representing 15% of all malignant
tumors (Beard et al, 1995; Netherlands Cancer Registry, 1989).
Approximately 30% of patients present with advanced disease,
and about 60% of these cases are no longer amenable to surgery.
The prognosis for these patients is poor.
The fluorinated pyrimidine 5-fluorouracil (5-FU) has been the
principal treatment for advanced colorectal cancer for the past 4
decades (Heidelberger et al, 1957). Therapy with 5-FU leads to
objective response in only 8–20% of patients, with few complete
responses and minimal improvement in survival (Carter, 1976;
Leichman et al, 1995; Moertel, 1982). Dosage of 5-FU is limited
by the occurrence of mucosal and neutropenic toxicities (Moertel,
1975).
Various modulating agents have been used in an attempt to
synergistically enhance 5-FU’s cytotoxicity. Results have so far
been disappointing. Improved response rates have been reported
with the combination of 5-FU and leucovorin, but responses were
mainly partial rather than complete and most were of short dura-
tion. Two randomized studies observed significantly increased
survival time for 5-FU with leucovorin (Ehrlichman et al, 1988;
Poon et al, 1989), but a meta-analysis and two other randomized
studies failed to confirm improvement over 5-FU monotherapy
(Piedbois et al, 1992; Leichman et al, 1995; O’Dwyer et al, 1996).
Early clinical trials reported encouraging results with the combina-
tion of 5-FU and interferon alpha (IFN-a), including tumor
response rates as high as 35–63% and median survival times of up
to 18 months. However, the cost was a high level of toxicity: in
particular, fever, constitutional symptoms and myelosuppression
(Wadler et al, 1989; Kemeny et al, 1990; Pazdur et al, 1990).
Unfortunately, no improvements in response rate or survival time
have been observed in further randomized trials of 5-FU with
IFN-a versus 5-FU monotherapy (Hill et al, 1995; Greco et al,
1996) or 5-FU with leucovorin (Corfu-A Study Group, 1995).
The interferons are a well-recognized group of naturally occur-
ring proteins with antiviral, immunomodulatory and antiprolifera-
tive properties. Based on antigenic specificity, physico-chemical
properties and cellular origin, they are classified as type I or type
II. The type I interferons, IFN-a and IFN-b, are produced by
leucocytes and fibroblasts respectively. IFN-b has a 30% level of
amino acid homology with IFN-a (Taniguchi et al, 1980), and
binds to the type I interferon receptor with higher affinity than
IFN-a (Ruzicka et al, 1987). There is evidence for a receptor-
associated protein specifically involved with IFN-b’s signalling
pathway and not IFN-a’s (Platanias et al, 1994). Although the
mechanisms of the interferons’ anti-tumor activity and 5-FU
modulation remain poorly understood, preclinical data suggest a
theoretical benefit for IFN-b over IFN-a in the treatment of
colorectal cancer. Antiproliferative activity against some tumor
cell lines in vitro appears greater for IFN-b than IFN-a (Borden
et al, 1982). IFN-b effectively inhibited the growth of several
human colon carcinoma cell lines in vitro, in a dose- and
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time-dependent fashion (Guglielmi et al, 1984; Wong et al, 1989).
Although IFN-b did not show marked activity against the C-1
colon cancer cell line, addition of IFN-b potentiated 5-FU’s effects
on C-1 cells in vitro (Kase et al, 1993). IFN-b has been shown to
increase in vitro expression of thymidine phosphorylase, thus
increasing the sensitivity of human colon carcinoma cells to 5-FU
(Schwartz et al, 1995). In a xenograft model (nude mice inoculated
with Co-4 colon cancer cells), IFN-b demonstrated dose-
dependent anti-tumor effects. In addition, the combination of IFN-
b and 5-FU demonstrated increased in vivo anti-tumor effects
compared to 5-FU monotherapy, which were not accompanied
by enhanced thymidylate synthetase inhibition (Kase et al, 1993).
At the inception of the phase II study reported here (protocol
GF5909), there were no published data available from clinical
trials of combined therapy with IFN-b and 5-FU. The study was
therefore undertaken to compare the effects of 5-FU given
with natural human IFN-b on response rate, time to disease
progression, survival time and safety to those of 5-FU
monotherapy in the treatment of patients with unresectable,
advanced colorectal carcinoma.
PATIENTS AND METHODS
Patient selection
Patients of either sex who met the following criteria were eligible
for the study: histologically proven metastatic, locally advanced, or
recurrent colorectal carcinoma no longer amenable to surgery and
measurable according to World Health Organization (WHO)
criteria; age at least 18 years; good Eastern Cooperative Oncology
Group performance status (ECOG ≤ 2) and life expectancy of ³ 3
months; normal cardiac and pulmonary function, and adequate
function of the bone marrow (haematocrit ³ 30%, thrombocytes
³ 100 l, granulocytes ³ 1.5 l), liver (bilirubin, alanine aminotrans-
ferase, g glutamyl transferase, and alkaline phosphatase ≤ 1.5 times
the upper limit of normal; higher values resulting from known
hepatic metastases were allowed) and kidneys (creatinine ≤ 1.5
times the upper limit of normal). Fertile women were required to use
effective contraception throughout the study. The following were
grounds for exclusion: previous chemotherapy (including 5-FU);
treatment with interferons or immunomodulators within the
previous year; brain and/or bone metastases as sole localization of
the tumor; lesions within previously irradiated fields; other invasive
neoplasms; current use of corticosteroids, acetylsalicylic acid, non-
steroidal anti-inflammatory drugs (NSAIDs), or barbiturates or
other medication interfering with protein synthesis; peptic ulcera-
tion; substance abuse; or psychiatric disorders.
Patients gave written informed consent for study participation
according to the modified Declaration of Helsinki (1989, Hong
Kong). The study was approved by the relevant local Ethics
Committees and the Spanish Ministry of Health, and was
conducted according to Good Clinical Practice. Patients could be
withdrawn from the study for major protocol violations, serious
intercurrent illnesses or adverse events, grade IV or persistent
grade III toxicities according to the WHO scale, disease progres-
sion, or interruption of treatment for more than 2 consecutive
weeks for any reason other than dose adjustment for toxicity.
Treatment plan
This was an open, randomized study conducted in four centers
in Spain. Following baseline evaluation, patients who met all
eligibility criteria were randomized in a 1:1 ratio to receive either
5-FU monotherapy or the combination of 5-FU and IFN-b for 52
weeks, or until disease progression or the occurrence of intolerable
toxicity. Randomization was performed centrally using a table of
random numbers, and was not stratified for prognostic factors.
For the first 5 days, all patients received a continuous intra-
venous (i.v.) infusion of 5-FU at a dose of 750 mg m–2 per day.
From day 15 until the end of the study, all patients received weekly
i.v. bolus injections of 750 mg m–2 5-FU, and patients randomized
to combination treatment received human fibroblast-derived
IFN-b (Frone®, Laboratorios Serono S.A., Madrid, Spain) as intra-
muscular (i.m.) injections of 9 M IU three times a week. This
schedule, previously reported for the combination of IFN-a and
5-FU (Wadler et al, 1989), has been used in other randomized
studies of IFNs with 5-FU.
Toxicity was assessed according to the modified WHO recom-
mendations for grading of acute and subacute toxicities (World
Health Organization, 1979). Dose modifications were made for
particular toxicities known to be associated with the study drugs:
for 5-FU, the dose could be reduced by 33% until the toxicity
resolved, or treatment could be interrupted for up to 2 weeks, to be
resumed at the reduced dose if toxicity resolved. It was recom-
mended that paracetamol be given for IFN-b-related side-effects
such as fever or constitutional symptoms; however, for specified
grade II or III toxicities the IFN-b dose was reduced by 33% until
resolution. In all cases, a maximum of 4 weeks was allowed for
resolution: if this did not occur, or if the toxicity recurred, the
patient was withdrawn from the study.
During the study paracetamol, NSAIDs, codeine and morphic
agents were allowed for symptomatic use only. Other medications
considered necessary for a patient’s welfare that would not
interfere with study medication or assessment were given at the
investigator’s discretion.
Following prestudy assessment, patients were monitored at
weekly intervals through physical examination and assessment of
body weight and hematological parameters. Biochemical analysis
was performed monthly. Carcinoembryonic antigen (CEA) levels,
patient performance status (ECOG) and tumor response were
measured at 8-weekly intervals. All assessments were performed
until treatment discontinuation.
Response criteria
The main efficacy variable, tumor response, was evaluated every 8
weeks using computerized tomography (CT) scan, X-ray, or ultra-
sound, and was assessed according to WHO response criteria
(World Health Organization, 1979). Clinically measurable disease
consisted of bidimensionally measurable lesions with clearly
defined margins on X-ray, CT scan, or ultrasound. Lesions serving
as measurable disease had to be at least 1 cm ´ 1 cm in size.
Complete response (CR) was defined as disappearance of all
known lesions lasting for at least 4 weeks. Partial response (PR)
referred to decrease by at least 50% in total tumor mass size,
lasting for at least 4 weeks, without occurrence of new lesions. No
change (NC) referred to a decrease in tumor mass size of less than
50%, or an increase of less than 25% determined on two occasions
at least 8 weeks apart, without new lesions. Progression of disease
(PD) was defined as an increase in tumor mass size of more than
25% or appearance of a new lesion. Secondary endpoints were
time to progression, defined as time between initiation of treat-
ment and first observation of PD, and survival time, defined as788 A Villar-Grimalt et al
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time between initiation of treatment and death or final analysis
(whichever came first). The main criterion for safety assessment
was occurrence of treatment-emergent toxicity.
Statistical methodology
Sample size was not calculated using statistical methodology
because this was a pilot study. It was assumed that 20 evaluable
patients per treatment arm would allow assessment of response
rates; therefore 51 patients were enrolled. Continuous variables
were assessed using Student’s t-tests; categorical variables,
including tumor response and safety measurements, were assessed
using the c2 or Fisher’s exact test as appropriate. Total time on
treatment and dose reductions for either drug were recorded
prospectively. Curves for overall survival time were calculated
using the Kaplan–Meier method, with results expressed as the
median with 95% confidence intervals. Distributions of survival
time and time to progression for the two treatments were compared
using the generalized Wilcoxon test (called ‘Breslow’ in SPSS
statistical software).
Two populations were analysed for efficacy. The intent-to-treat
population included all eligible and randomized patients. The
evaluable patient population included all randomized patients
without major protocol violations who underwent at least one
assessment of tumor response. All randomized patients were
included in the safety analysis, which was performed using the
Fisher’s exact and c2 tests.
RESULTS
Patients
From 8 March 1993 to 25 November 1994, a total of 51 patients
were randomized to receive 5-FU monotherapy (n = 26) or
5-FU–IFN-b combination therapy (n = 25). Two randomized
patients in the 5-FU group were found ineligible (one patient was
using an NSAID at enrollment and the other had non-measurable
disease) and were therefore excluded from the intent-to-treat popu-
lation (n = 49). A further six patients, two from the 5-FU group
and four from the 5-FU–IFN-b group, were excluded from the
evaluable patient population (n = 43) because of major protocol
violations or lack of assessments of response.
Demographic and baseline characteristics are shown in Table 1.
No baseline variables differed significantly between treatment
groups. The most common site of measurable lesions was the liver
(74.1% and 64.3% of patients in the 5-FU and 5-FU–IFN-b groups
respectively), with the lungs being the next most frequent location
(14.8% and 17.9% of patients respectively).
Treatment dosage and duration
The mean weekly 5-FU dose was significantly higher for the 5-FU
monotherapy group (1082 mg) than for the 5-FU–IFN-b combina-
tion therapy group (935 mg; P = 0.022, t-test). The mean 5-FU
dose intensity was also significantly higher for the 5-FU group
(82.9% vs 73.5%; P = 0.015, t-test).
No patients in the 5-FU group completed the planned treatment
period, compared to four patients (16%) in the 5-FU–IFN-b group.
The mean treatment duration for the 5-FU–IFN-b group, at
30.4 weeks, was nearly double that for the 5-FU group (13.6
weeks; P < 0.001, t-test), and the cumulative dose of 5-FU was
significantly higher in the 5-FU–IFN-b group (29.527 vs 15.394 g;
P = 0.001, t-test). The mean weekly dose of IFN-b administered
(22.3 ± 5.6 M IU per week) was close to the proposed dose of 27 M
IU per week.
The 5-FU dose was modified for 88% of patients in the 5-FU
group and 92% in the 5-FU–IFN-b group. The proportion of
patients requiring both 5-FU dose reduction and treatment inter-
ruption was higher in the 5-FU–IFN-b group (82.6% vs 52.4%;
P = 0.02, Fisher). The IFN-b dose was adjusted in 84% of patients
receiving combined treatment.
Efficacy
Results are presented for the intent-to-treat population (n = 49).
Objective tumor response is also presented for evaluable patients
(n = 43).
Among evaluable patients, an overall tumor response rate of 4.5%
was observed in the 5-FU group (one PR), compared with a rate of
33.3% in the 5-FU–IFN-b group (two CR and five PR; P = 0.021,
Fisher). The majority of patients in both groups showed no change
(12 of 22 in the 5-FU and 11 of 21 in the 5-FU–IFN-b groups).
Table 1 Patient baseline characteristics
5-FU 5-FU–IFN-b
Eligible and randomized patients (n = 24) (n = 25)
No. % No. %
Sex (% female) 46 40
Age in years (mean ± SD) 62.0 (± 7.6) 65.2 (± 6.7)
Weight in kg (mean ± SD) 70.9 (± 9.6) 65.4 (± 12.4)
ECOG performance status
0–1 17 70.8 23 92
2 7 29.2 2 8
Diagnosis of disease
Locally advanced 0 0 0 0
Metastatic 22 91.6 18 72
Recurrent 1 4.2 4 16
Local and metastatic 0 0 1 4
Metastatic and recurrent 1 4.2 2 8
Primary tumour site
Ascending colon 4 16.7 4 16
Descending colon 2 8.3 3 12
Sigmoid colon 2 8.3 7 28
Rectum–sigmoid colon 5 20.8 4 16
Rectum 10 41.7 5 20
Undefined colon 1 4.2 2 8
Histological grade
Gx 6 25 9 36
G1 1 4.2 3 12
G2 16 66.7 11 44
G3 1 4.2 2 8
Dukes’ stage
A 2 8.3 2 8
B 2 8.3 0 0
C 6 25 4 16
D 14 58.3 17 68
Unknown 0 0 2 8
Measurable lesions
Pelvic mass 1 3.7 3 10.7
Liver 20 74.1 18 64.3
Lung 4 14.8 5 17.9
Suprarenal 1 3.7 0 0
Adenopathies 0 0 1 3.6
Retroperitoneal 1 3.7 1 3.6
CEA in ng ml–1 (mean ± s.d.)
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Intent-to-treat analysis of tumor response rate supported this
significant finding (response rates 4.17% and 28% for 5-FU and
5-FU–IFN-b respectively; P = 0.0488). In the intent-to-treat popu-
lation, median time to disease progression was significantly
shorter in the 5-FU group (4.2 months; 95% CI 2.7–5.4) than in the
5-FU–IFN-b group (7.2 months; 95% CI 6.1–8.2; P = 0.0435,
Breslow).
Figure 1 shows the Kaplan–Meier estimates of survival function
for time to death (from any cause) in the intent-to-treat population.
Median survival time was significantly shorter in the 5-FU group
(7.2 months; 95% CI 4.8–9.7) than in the 5-FU–IFN-b group
(15.9 months; 95% CI 10.4–21.3; P = 0.038, Breslow). At 12
months, six patients in the 5-FU group (27.3%) and 14 patients in
the 5-FU–IFN-b group (66.7%) were still alive. Rescue treatment
was given, after discontinuation of the study treatment, to seven
patients in 5-FU group (29.2%) and to nine patients in the 5-FU–
IFN-b group (36%) (P = 0.84, c2).
Tolerability and safety
Toxicities are presented by WHO grade in Table 2. For each cate-
gory, each patient is represented by the highest-grade toxicity
experienced. Two patients from each treatment group experienced
grade IV neutropenia; no other grade IV toxicities were observed.
Few patients experienced clinically significant hematological toxi-
city (³ grade I), as reflected by weekly assessment of hemoglobin
level and neutrophil and platelet counts.
The only statistically significant difference between the groups
was a higher frequency of fever in the 5-FU–IFN-b group (68% vs
31%;  P = 0.008, c2). Two patients who received 5-FU–IFN-b
experienced grade III fever. Three cases of grade III diarrhea
occurred in the 5-FU and two in the 5-FU–IFN-b groups (P = 0.27,
Fisher). Grade III mucositis/stomatitis requiring interruption of
5-FU occurred in three patients in the 5-FU and four in the
5-FU–IFN-b groups (P = 0.67, Fisher). Grade II/III skin toxicity
requiring 5-FU dose reduction occurred in four and six patients in
the 5-FU and 5-FU–IFN-b groups respectively (P = 0.46, Fisher),
and grade II or higher neurological toxicity was observed in eight
and seven patients respectively (P = 0.29, Fisher).
DISCUSSION
Compared to published results concerning modulation of 5-FU by
IFN-a in treatment of advanced colorectal cancer, clinical data on
IFN-b in this indication are limited. Nevertheless, IFN-b compares
favorably with IFN-a in its capacity to inhibit the growth of colon
cancer cells (Guglielmi et al, 1984; Wong et al, 1989), to modulate
5-FU in vitro (Kase et al, 1993), and to express receptor and post-
receptor signal transduction activity (Platanias et al, 1994). The
combination of 5-FU and IFN-b was therefore of prime interest.
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Figure 1 Survival time: Kaplan–Meier estimates of survival function for the intent-to-treat population. A statistically significant increase in survival occurred with
the addition of IFN-b to 5-FU (Breslow, P = 0.038)
Table 2 Haematological and non-haematological toxicity
Grade I–II toxicity Grade III–V toxicity
5-FU 5-FU–IFN-b 5-FU 5-FU–IFN-b
(n = 26) (n = 25) (n = 26) (n = 25)
Haemoglobin 10 9 2 2
Neutrophils 9 11 6 6
Thrombocytes 6 4 0 0
Diarrhoea 12 17 3 2
Mucositis/stomatitis 13 14 3 4
Vomiting 19 12 1 4
Conjunctivitis 4 8 1 0
Cutaneous toxicity 8 6 2 2
Fever* 8 15 0 2
Lethargy 2 6 0 1
Infection 1 2 1 1
Alopecia 2 4 0 1
Ataxia 4 4 0 1
Neurological toxicity 9 12 2 3
No significant differences were observed for toxicity, except for grouped
grade I + II versus grade III + IV fever* (Fisher, P = 0.016).790 A Villar-Grimalt et al
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This randomized phase II trial studied the effect of 5-FU–IFN-b on
tumor response in comparison with 5-FU monotherapy in
chemotherapy-naive patients with unresectable, advanced
colorectal cancer. The two treatment groups were well balanced
(Table 1): Dukes’ D disease was more common in the 5-FU–IFN-
b group, and more patients in the 5-FU group had poor perfor-
mance status (ECOG 2); these differences were not statistically
significant.
The tumor response rate among evaluable patients in this study
was 33.3% in the 5-FU–IFN-b group; only one patient receiving
monotherapy (4.5%) showed objective response. Intent-to-treat
analysis supported this finding (tumor response rates 28% and
4.17% for combined therapy and monotherapy respectively).
Although any comparison of efficacy between studies requires
caution, the response rate seen with 5-FU monotherapy appears
low compared to results of other randomized trials using the same
5-FU schedule (Hill et al, 1995; Dufour et al, 1996; Greco et al,
1996). The response rate seen with 5-FU–IFN-b is consistent with
results from the only published study to use 5-FU with IFN-b in
chemotherapy-naive patients with advanced colorectal cancer
(35%; Wadler et al, 1995) and from randomized studies of 5-FU
with IFN-a that used the same 5-FU schedule (Corfu-A Study
Group, 1995; Hill et al, 1995; Dufour et al, 1996; Greco et al,
1996; Jäger et al, 1996): these studies reported response rates
between 21% and 30%. Randomized trials of 5-FU with
leucovorin, using different 5-FU schedules, reported similar
rates (18–39%; Piedbois et al, 1992; Corfu-A Study Group, 1995;
Köhne et al, 1995; Leichman et al, 1995; Jäger et al, 1996).
In the present study, intent-to-treat analysis showed a 71%
increase in median time to disease progression for 5-FU–IFN-b
compared to monotherapy (7.2 vs 4.2 months). Median survival
was also significantly increased by the addition of IFN-b to 5-FU:
in the intent-to-treat analysis, from 7.2 to 15.9 months. The
patients who received rescue treatment (high-dose continuous i.v.
infusion of 5-FU, UFT with or without leucovorin) after discontin-
uation of study treatment were equally distributed between the two
groups. The median survival time reported for patients receiving
5-FU with either IFN-a or leucovorin approximates 12 months.
Combination of 5-FU with recombinant IFN-b showed a median
survival time of 15 months (Wadler et al, 1995). To date, only one
randomized study of 5-FU with IFN-a has reported significant
improvement in survival time compared to monotherapy (Dufour
et al, 1996); three others have observed no significant benefit (Hill
et al, 1995; Greco et al, 1996; O’Dwyer et al, 1996). Although two
studies showed significant increases in survival time using leucov-
orin with 5-FU (Ehrlichman et al, 1988; Poon et al, 1989), a meta-
analysis including these studies and seven others (Piedbois et al,
1992) could not confirm improvement over 5-FU monotherapy. In
addition, a multi-armed randomized study using different 5-FU
regimens with or without leucovorin failed to demonstrate differ-
ences in survival between 5-FU with leucovorin and 5-FU only
(Leichman et al, 1995).
Improved efficacy must always be weighed against treatment-
emergent toxicities. In the current study, the only significant
difference in toxicity between the two treatments was a higher
occurrence of fever with 5-FU–IFN-b. Grade III fever occurred in
two patients receiving 5-FU–IFN-b; no grade IV fever occurred.
Patients received paracetamol for flu-like symptoms, which are
well-recognized side-effects of interferon therapy and are gener-
ally transient and self-limiting. Treatment with 5-FU–IFN-b was
not associated with more neurological toxicity, myelosuppression,
or gastrointestinal toxicity than 5-FU monotherapy. No grade IV
toxicities were observed, with the exception of two cases of
neutropenia in each treatment group. No patients were withdrawn
from the study or hospitalized because of adverse events.
The combination of 5-FU and IFN-b may be less toxic than
5-FU with IFN-a. Combinations of 5-FU with IFN-a and with
leucovorin were compared in a randomized trial using the same
5-FU schedule as the present study for the 5-FU–IFN-a group
(Corfu-A Study Group, 1995). With the caution necessary when
comparing different studies, it would appear that combined grade
III and IV hematological toxicity was less common with IFN-b
than with IFN-a, particularly with regard to neutropenia (24% vs
74%). Occurrences of grade III and IV mucositis/stomatitis and
vomiting were similar for the two interferons, while diarrhea was
more frequent with 5-FU–IFN-a than with 5-FU–IFN-b (35% and
8% respectively). The mean cumulative 5-FU dose was signifi-
cantly lower in the monotherapy group than in the 5-FU–IFN-b
group: more patients in the monotherapy group discontinued treat-
ment because of disease progression. Approximately 90% of
patients in both groups required 5-FU dose adjustments for toxi-
city. The IFN-b dose was also adjusted in the majority of patients
receiving combined treatment.
In conclusion, this randomized pilot study demonstrated a
synergistic anti-tumor action for 5-FU and natural IFN-b in the
treatment of chemotherapy-naive patients with advanced
colorectal cancer. The combination resulted in both increased
tumor response and improved survival, without higher levels of
clinically relevant drug-related toxicity. The toxicity profile of
IFN-b plus 5-FU may compare favorably to that of 5-FU and IFN-
a, suggesting that 5-FU–IFN-b may be a promising alternative for
the treatment of advanced colorectal cancer. A multicenter,
randomized phase III trial comparing 5-FU–IFN-b to standard
treatment has been initiated recently.
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